Karl Broich

Department of Neuropsychopharmacology, Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM)

Affiliated withFederal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM)Federal Institute for Drugs and Medical Devices Federal Institute for Drugs and Medical Devices (BfArM)

Research Area

Biography

Karl Broich has not added Biography.
If you are Karl Broich and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 3	Year
Publication title Cited by 21	2016
Publication title Cited by 5	2017
Publication title Cited by 10	2019

Other Publications

Article	Year
Placebo-controlled studies in depression: necessary, ethical and feasible. European archives of psychiatry and clinical neuroscience\| PubMed ID: 12664309	2003
Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: an exploratory approach. Psychiatry research\| PubMed ID: 16043331	2005
Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. European archives of psychiatry and clinical neuroscience\| PubMed ID: 16078087	2006
Regulatory issues in vascular dementia: a European perspective. International psychogeriatrics / IPA\| PubMed ID: 16191258	2003
Mild cognitive impairment. Lancet (London, England)\| PubMed ID: 16631882	2006
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects. Thrombosis and haemostasis\| PubMed ID: 17003918	2006
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. Journal of psychopharmacology (Oxford, England)\| PubMed ID: 17060346	2006
Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective. International psychogeriatrics / IPA\| PubMed ID: 17433121	2007
Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology\| PubMed ID: 19269795	2009
Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues in clinical neuroscience\| PubMed ID: 19585950	2009
Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. Journal of neurology, neurosurgery, and psychiatry\| PubMed ID: 19770163	2010
Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. European archives of psychiatry and clinical neuroscience\| PubMed ID: 19888620	2010
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature reviews. Drug discovery\| PubMed ID: 20592748	2010
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report. The Journal of clinical psychiatry\| PubMed ID: 20673551	2010
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. The Journal of clinical psychiatry\| PubMed ID: 20797373	2010
Anticholinergic drug use and risk for dementia: target for dementia prevention. European archives of psychiatry and clinical neuroscience\| PubMed ID: 20960005	2010
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. Journal of neural transmission (Vienna, Austria : 1996)\| PubMed ID: 21755462	2012
Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements. Progress in neurobiology\| PubMed ID: 21945642	2011
Burnout: a fashionable diagnosis. Deutsches Ärzteblatt international\| PubMed ID: 22163259	2011
Voltage-gated Ca(2+) channel mediated Ca(2+) influx in epileptogenesis. Advances in experimental medicine and biology\| PubMed ID: 22453990	2012
DSM-5 and clinical trials in psychiatry: challenges to come? Nature reviews. Drug discovery\| PubMed ID: 22850770	2012
[Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency]. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen\| PubMed ID: 23663906	2013
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimer's & dementia : the journal of the Alzheimer's Association\| PubMed ID: 23809364	2013
[Personalised medicine]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz\| PubMed ID: 24170074	2013
Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochemical pharmacology\| PubMed ID: 24275164	2014
Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval. Alzheimer's & dementia : the journal of the Alzheimer's Association\| PubMed ID: 24418060	2014
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association\| PubMed ID: 24751826	2015
The CaV2.3 R-type voltage-gated Ca2+ channel in mouse sleep architecture. Sleep\| PubMed ID: 24790266	2014
Addressing the regulatory and scientific challenges in multiple sclerosis--a statement from the EU regulators. Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 25160121	2014
Risk of dementia in elderly patients with the use of proton pump inhibitors. European archives of psychiatry and clinical neuroscience\| PubMed ID: 25341874	2015
[Safety of medical devices]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz\| PubMed ID: 25394355	2014
Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert review of neurotherapeutics\| PubMed ID: 25537424	2015
The European Medicines Agency's strategies to meet the challenges of Alzheimer disease. Nature reviews. Drug discovery\| PubMed ID: 25829266	2015
Limited effects of an eIF2αS51A allele on neurological impairments in the 5xFAD mouse model of Alzheimer's disease. Neural plasticity\| PubMed ID: 25883808	2015
Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer's disease. Neural plasticity\| PubMed ID: 25922768	2015
Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's disease : JAD\| PubMed ID: 26402088	2015
Identification and validation of biomarkers for autism spectrum disorders. Nature reviews. Drug discovery\| PubMed ID: 26718285	2016
EEG Radiotelemetry in Small Laboratory Rodents: A Powerful State-of-the Art Approach in Neuropsychiatric, Neurodegenerative, and Epilepsy Research. Neural plasticity\| PubMed ID: 26819775	2016
Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA neurology\| PubMed ID: 26882076	2016
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & dementia : the journal of the Alzheimer's Association\| PubMed ID: 27012484	2016
Drug Regulation and Pricing--Can Regulators Influence Affordability? The New England journal of medicine\| PubMed ID: 27168431	2016
Sampling rate, signal bandwidth and related pitfalls in EEG analysis. Journal of neuroscience methods\| PubMed ID: 27172844	2016
The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future? Multiple sclerosis (Houndmills, Basingstoke, England)\| PubMed ID: 27465615	2016
Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data. Journal of Alzheimer's disease : JAD\| PubMed ID: 27567804	2016
The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics. Biomarkers in medicine\| PubMed ID: 27661101	2016
[Improving drug licensing for children and adolescents : Position paper from the More Medicines for Minors Symposion 8 June 2015 in Bonn]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz\| PubMed ID: 27778087	2016
Gender-Specific Hippocampal Dysrhythmia and Aberrant Hippocampal and Cortical Excitability in the APPswePS1dE9 Model of Alzheimer's Disease. Neural plasticity\| PubMed ID: 27840743	2016
Review: Cav2.3 R-type Voltage-Gated Ca(2+) Channels - Functional Implications in Convulsive and Non-convulsive Seizure Activity. The open neurology journal\| PubMed ID: 27843503	2016
Motor Cortex Theta and Gamma Architecture in Young Adult APPswePS1dE9 Alzheimer Mice. PloS one\| PubMed ID: 28072877	2017